Kota Kubo

Kota Kubo graduated from the University of Tokyo Graduate School of Engineering. In 2013, while enrolled at the University of Tokyo, he began researching and developing software and algorithms that simulate the relationship between doctors, symptoms and disease names. He worked at M3 Corporation for about three years, working on software development and web marketing in the BtoC healthcare field, including doctor Q&A services. In 2017, he founded Ubie with his co-representative doctor Abe.

Posts by Kota Kubo

MedCity Influencers

Provider Feedback Loop: The Missing Link in AI Development, Use and Adoption

With the right solutions, providers can spend more time with the patient, building the relationship, earning their trust, and focusing on the forward-looking health journey.

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

A Personalized Approach to Medication Nonadherence

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.